| AASLD |
American Association for the Study of Liver Diseases |
| ACOG |
American College of Obstetricians and Gynecologists |
| ALT |
alanine aminotransferase |
| anti-HBc |
anti-hepatitis B core antibody |
| anti-HBS |
hepatitis B surface antibody |
| aOR |
adjusted odds ratio |
| aHR |
adjusted hazard ratio |
| aRR |
adjusted risk ratio |
| ART |
antiretroviral therapy |
| ARV |
antiretroviral |
| AUC |
area under the curve |
| AUC0-12h |
area under the curve from 0 to 12 hours |
| BMC |
bone mineral content |
| BMD |
bone mineral density |
| BMI |
body mass index |
| BHIVA |
British HIV Association |
| C12h |
concentration at 12 hours postdose |
| C24h |
concentration at 24 hours postdose |
| CAR |
chimeric antigen receptor |
| CD4 |
CD4 T lymphocyte |
| CDC |
Centers for Disease Control and Prevention |
| CI |
confidence interval |
| Cmax |
maximum plasma concentration |
| Cmin |
minimum plasma concentration |
| Ctrough |
trough concentration |
| CNS |
central nervous system |
| CrCl |
creatinine clearance |
| CYP |
cytochrome P450 |
| CYP3A4 |
cytochrome P450 3A4 |
| DAA |
direct-acting antiviral |
| DBS |
dried blood spots |
| EC |
enteric coated |
| EC90 |
90% maximal effective concentration |
| ePPND |
enhanced Pre- and Postnatal Development |
| FDA |
U.S. Food and Drug Administration |
| FDC |
fixed-dose combination |
| GMC |
geometric mean concentration |
| gp |
glycoprotein |
| HAV |
hepatitis A virus |
| HBIG |
hepatitis B immune globulin |
| HBcAb |
hepatitis B core antibody |
| HBeAb |
hepatitis B e antibody |
| HBeAg |
hepatitis B e antigen |
| HbsAb |
hepatitis B surface antibody |
| HbsAg |
hepatitis B surface antigen |
| HBV |
hepatitis B virus |
| HCV |
hepatitis C virus |
| HCAZ |
head circumference–for–age z-scores |
| HEU |
HIV exposed but uninfected |
| HD |
high dose |
| HDP |
hypertensive disorders of pregnancy |
| HUU |
HIV unexposed and uninfected |
| HR |
hazard ratio |
| HRSA |
Health Resources and Services Administration |
| HSR |
hypersensitivity reaction |
| IC50 |
inhibitory concentration 50% |
| IGF |
insulin-like growth factor |
| IgG |
immunoglobulin G |
| IM |
intramuscular |
| INSTI |
integrase strand transfer inhibitor |
| IPV |
intimate partner violence |
| IQR |
interquartile range |
| IDSA |
Infectious Diseases Society of America |
| IUD |
intrauterine device |
| IUPC |
intrauterine pressure catheter |
| IV |
intravenous/intravenously |
| LARC |
long-acting reversible contraceptive |
| LAZ |
length-for-age z-scores |
| LBW |
low birth weight |
| mtDNA |
mitochondrial DNA |
| NAT |
nucleic acid test |
| NAT2 |
N-acetyltransferase 2 |
| NHSS |
National HIV Surveillance System |
| NICHD |
National Institute of Child Health and Human Development |
| NIH |
National Institutes of Health |
| NNRTI |
non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor |
| nPEP |
non-occupational post-exposure prophylaxis |
| NRTI |
nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor |
| NTD |
neural tube defect |
| OARAC |
Office of AIDS Research Advisory Council |
| OI |
opportunistic infection |
| OR |
odds ratio |
| The Panel |
The Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission |
| PBMC |
peripheral blood mononuclear cells |
| PBPK |
physiologically based pharmacokinetic |
| PJP |
Pneumocystis jirovecii pneumonia |
| PCR |
polymerase chain reaction |
| PI |
protease inhibitor |
| PK |
pharmacokinetic |
| PO |
orally |
| POC |
point of care |
| PPI |
proton pump inhibitor |
| PrEP |
pre-exposure prophylaxis |
| PTB |
preterm birth |
| RAM |
resistance-associated mutation |
| RCT |
randomized controlled trial |
| RDS |
respiratory distress syndrome |
| ROM |
rupture of membranes |
| RR |
relative risk |
| SGA |
small for gestational age |
| sPTB |
spontaneous preterm birth |
| STI |
sexually transmitted infection |
| t1/2app |
terminal-phase half-life |
| TB |
tuberculosis |
| Tdap |
tetanus, diphtheria and pertussis |
| TDM |
therapeutic drug monitoring |
| UGT |
uridine diphosphate glucuronosyltransferase |
| vPTB |
very preterm birth |
| VL |
viral load |
| vSGA |
very small for gestational age |
| WAZ |
weight-for-age z-scores |
| WHO |
World Health Organization |
